What assessment and management plan should hematology recommend for a patient with a history of stroke and myocardial infarction with coronary stenting, prior anabolic‑steroid use, who has discontinued apixaban (Eliquis) and clopidogrel (Plavix) due to refill issues, and who previously had a negative hypercoagulable workup?

Hematology Assessment and Plan

This patient requires immediate reinitiation of dual antiplatelet therapy (aspirin + clopidogrel) given his extremely high thrombotic risk from prior MI with stenting and stroke, with urgent assistance to obtain medication access. The discontinued anticoagulation and antiplatelet therapy places him at imminent risk for stent thrombosis and recurrent stroke.

Immediate Actions Required

1. Restart Antiplatelet Therapy Urgently

Reinitiate dual antiplatelet therapy (DAPT) immediately:

• Aspirin 81 mg daily (lifelong) 1
• Clopidogrel 75 mg daily (lifelong given his history) 1

The 2024 ESC guidelines are unequivocal: in patients with prior MI and coronary stenting, aspirin 75-100 mg daily is recommended lifelong after the initial DAPT period 1. Clopidogrel is recommended as equally effective alternative or in combination depending on timing from stent placement 1.

2. Address the Apixaban Question

Discontinue apixaban and do not restart unless there is a clear indication for anticoagulation that you haven't mentioned (atrial fibrillation, documented LV thrombus, or other specific indication). Here's why:

• No hypercoagulable disorder identified: His negative hypercoagulable workup means there's no intrinsic thrombophilia requiring anticoagulation 1
• Anabolic steroid history is relevant but not an indication for anticoagulation: While anabolic steroids increase thrombotic risk (including documented cases of stent thrombosis even on DAPT 2), this is managed with antiplatelet therapy, not anticoagulation
• Stroke etiology matters: If his stroke was cardioembolic from atrial fibrillation, he needs anticoagulation. If atherosclerotic/thrombotic, he needs antiplatelet therapy 3, 4

3. Determine If Anticoagulation Is Actually Indicated

You must clarify the stroke mechanism:

• If atrial fibrillation with CHA₂DS₂-VASc ≥2: Restart anticoagulation (preferably apixaban 5 mg twice daily, or 2.5 mg twice daily if age ≥80, weight ≤60 kg, or creatinine ≥1.5 mg/dL) 1, 5
• If atherothrombotic stroke without AF: Anticoagulation is NOT indicated; DAPT alone is appropriate 3, 4
• If documented LV thrombus: Anticoagulation is required, but warfarin may be superior to DOACs in this specific scenario 6

Specific Management Algorithm

Scenario A: No Indication for Anticoagulation (Most Likely)

Regimen:

• Aspirin 81 mg daily + Clopidogrel 75 mg daily indefinitely 1
• Add high-intensity statin if not already on one 1
• Add PPI for GI protection given dual antiplatelet therapy 7

Scenario B: Atrial Fibrillation Requiring Anticoagulation

If >12 months post-stent:

• Apixaban 5 mg twice daily (or 2.5 mg twice daily if dose-reduction criteria met) 5
• Plus aspirin 81 mg daily OR clopidogrel 75 mg daily (choose one, not both) 1
• The 2024 ESC guidelines state that aspirin or clopidogrel "may be considered" in addition to OAC in patients with AF, history of MI, and high ischemic risk who don't have high bleeding risk 1

If <12 months post-stent (especially if <6 months):

• This requires triple therapy initially, then de-escalation
• Apixaban + clopidogrel 75 mg daily (drop aspirin after 1 week if low stent thrombosis risk) 1
• Continue dual therapy (apixaban + clopidogrel) for up to 6-12 months depending on ischemic risk 1
• Then apixaban monotherapy

Scenario C: Documented LV Thrombus

Consider warfarin over apixaban:

• Recent case reports show treatment failure with apixaban for LV thrombus 6
• Warfarin (INR 2.0-3.0) remains the standard 8, 6
• Plus clopidogrel 75 mg daily (safer than triple therapy with aspirin) 9, 10
• Duration: Until thrombus resolution confirmed on imaging

Critical Pitfalls to Avoid

1. Do not leave him without antiplatelet therapy: Even brief interruptions increase stent thrombosis risk dramatically, especially with his anabolic steroid history which independently increases thrombotic risk 2

2. Do not assume he needs anticoagulation: The negative hypercoagulable workup argues against intrinsic thrombophilia. His events are likely atherothrombotic, requiring antiplatelet therapy

3. Medication access is the real issue: Work with social work/pharmacy to:

   • Obtain manufacturer assistance programs
   • Switch to generic alternatives (generic apixaban now available)
   • Consider aspirin + clopidogrel alone if anticoagulation not truly indicated (much cheaper)

4. Anabolic steroid counseling: Document cessation, counsel on cardiovascular risks, and consider endocrinology referral for hypogonadism management if relevant

Bleeding Risk Mitigation

• PPI therapy mandatory with DAPT 7
• Avoid NSAIDs 7
• Radial access for any future procedures 7
• If on warfarin: Tight INR control (target 2.0-2.5 if on dual therapy) 8, 9

Follow-Up Plan

• 2 weeks: Confirm medication adherence, check CBC
• 1 month: Reassess for bleeding complications
• 3-6 months: Consider de-escalation strategy if on triple therapy
• Ongoing: Ensure continuous medication access through assistance programs

The priority is getting him back on antiplatelet therapy immediately—every day without it increases his risk of catastrophic stent thrombosis or recurrent stroke.